(0.26%) 5 145.00 points
(0.15%) 38 499 points
(0.40%) 17 918 points
(-0.58%) $83.36
(0.78%) $1.938
(0.00%) $2 347.10
(0.21%) $27.59
(2.43%) $944.55
(-0.20%) $0.933
(-0.24%) $11.00
(-0.37%) $0.797
(1.32%) $93.09
@ $0.771
発行日: 15 2月 2024 @ 03:55
リターン: -10.52%
前回のシグナル: 2月 14 - 05:34
前回のシグナル:
リターン: -0.05 %
Live Chart Being Loaded With Signals
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States...
Stats | |
---|---|
本日の出来高 | 526 741 |
平均出来高 | 2.69M |
時価総額 | 82.36M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-0.370 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.260 |
ATR14 | $0.00200 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Fust Matthew K | Buy | 150 000 | Common Stock |
2024-03-31 | Heiden William K | Buy | 150 000 | Common Stock |
2024-03-31 | Roncarolo Maria Grazia | Buy | 150 000 | Common Stock |
2024-03-31 | Gallagher Carol Giltner | Buy | 150 000 | Common Stock |
2024-03-31 | Mallik Ameet | Buy | 150 000 | Common Stock |
INSIDER POWER |
---|
70.32 |
Last 100 transactions |
Buy: 8 350 944 | Sell: 2 074 393 |
ボリューム 相関
Atara Biotherapeutics Inc 相関
10 最も負の相関 | |
---|---|
MCAA | -0.951 |
MSDA | -0.949 |
CITE | -0.945 |
DHAC | -0.944 |
AHRN | -0.942 |
LEGA | -0.942 |
ADAL | -0.942 |
FTAA | -0.94 |
PFTA | -0.939 |
ZING | -0.939 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Atara Biotherapeutics Inc 相関 - 通貨/商品
Atara Biotherapeutics Inc 財務諸表
Annual | 2023 |
収益: | $8.57M |
総利益: | $-313 000 (-3.65 %) |
EPS: | $-2.61 |
FY | 2023 |
収益: | $8.57M |
総利益: | $-313 000 (-3.65 %) |
EPS: | $-2.61 |
FY | 2022 |
収益: | $63.57M |
総利益: | $49.01M (77.08 %) |
EPS: | $-2.24 |
FY | 2021 |
収益: | $20.34M |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.63 |
Financial Reports:
No articles found.
Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。